Preventing recurrent preterm delivery with prophylactic vaginal progesterone

Summaries 1 min 131

Font Size

Created On: 21/11/2025

This study sought to explore the effectiveness of prophylactic vaginal progesterone in minimizing the risk of preterm birth among women with a prior history of spontaneous preterm delivery.

See All

Key take away

Prophylactic vaginal progesterone supports gestational prolongation in women at risk of preterm birth.

Background

This study sought to explore the effectiveness of prophylactic vaginal progesterone in minimizing the risk of preterm birth among women with a prior history of spontaneous preterm delivery.

Method

A total of 125 women (mean age 29 years) with a history of preterm birth were enrolled. Baseline demographic, medical, and obstetric information was procured before treatment. Participants self-administered vaginal progesterone daily and attended follow-up visits at the study center every 2 weeks. The intervention continued up to 36 weeks of gestation. Standard care for preterm labor was offered when necessary. All data were recorded via a standardized collection form.

Result

Of the cohort, 38% were primiparous, while 62% had prior deliveries. Among the 125 women studied, 88% attained successful pregnancy outcomes following prophylactic vaginal progesterone therapy. At delivery time, the average gestational age was 34 weeks (standard deviation ± 3.46). Although these results portray a positive trend, the absence of a control group (placebo or untreated) restricts the ability to calculate a precise p-value for statistical significance. Nevertheless, the observed 88% success rate suggests a potential benefit, supporting the current use of vaginal progesterone in women at heightened risk for recurrent preterm birth.

Conclusion

Prophylactic vaginal progesterone was linked with an 88% reduction in preterm birth among women with a history of spontaneous preterm delivery, highlighting its potential to boost outcomes in this high-risk population. Individual treatment decisions should consider patient-specific risk factors in consultation with a healthcare provider.